SRPT — Sarepta Therapeutics, Inc. stock price, charts and financials

QT36Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
16.39
+0.51+3.21%
OverviewShort InterestFilings
SRPTQT36Sarepta Therapeutics, Inc.·NASDAQ
16.39+3.21%
Earnings
Up 3.2% — Reported earnings — EPS beat by 224%, revenue beat by 54%.
High confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OCUL+2.26%$8.59MESO+2.28%$14.80AUPH+2.47%$14.93TYRA+1.53%$32.53URGN+3.45%$39.92IOVA+0.93%$4.36STOK+7.14%$31.67TSHA+7.27%$6.20
Snapshot
Index-P/E23.97EPS (ttm)-0.96Insider Own7.67%Shs Outstand105.58MPerf Week6.22%
Market Cap1.73BForward P/E19.16EPS next Y0.86Insider Trans-0.09%Shs Float94.61MPerf Month-14.55%
Enterprise Value2.11BPEG-EPS next Q-Inst Own-Short Float30.11%Perf Quarter-25.64%
Income65.00MP/S0.79EPS this Y482.56%Inst Trans-Short Ratio8.69Perf Half Y-20.90%
Sales2.18BP/B1.15EPS next Y-76.71%ROA2.05%Short Interest28.49MPerf YTD-23.84%
Book/sh14.26P/C2.65EPS next 5Y-49.69%ROE4.89%52W High25.32 -35.27%Perf Year3.02%
Cash/sh6.19P/FCF14.78EPS past 3/5Y-ROIC-1.53%52W Low14.68 11.65%Perf 3Y-84.90%
Dividend Est.-EV/EBITDA16.92Sales past 3/5Y33.06% 32.41%Gross Margin62.39%Volatility5.38% 5.23%Perf 5Y-75.26%
Dividend TTM-EV/Sales0.97EPS Y/Y TTM-141.03%Oper. Margin-1.88%ATR (14)0.89Perf 10Y-30.76%
Dividend Ex-Date-Quick Ratio2.62Sales Y/Y TTM14.83%Profit Margin2.98%RSI (14)47.59Recom2.55
Dividend Gr. 3/5Y-Current Ratio4.63EPS Q/Q192.40%SMA20-3.16%Beta0.22Target Price25.11
Payout0.00%Debt/Eq0.90Sales Q/Q-1.88%SMA50-3.03%Rel Volume0.84Prev Close15.88
Employees835LT Debt/Eq0.90EarningsAug 05SMA200-15.34%Avg Volume3.42MPrice16.39
IPO DateJun 04, 1997Option/ShortYes / YesEPS/Sales Surpr.223.80% 54.13%Net Debt/EBITDA4.58Volume2,874,186Change3.21%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-27-26ReiteratedMorgan StanleyEqual Weight$25
Jul-09-26UpgradeWolfe ResearchPeer Perform → Outperform$27
Jul-09-26ReiteratedPiper SandlerNeutral$16 → $20
May-15-26ReiteratedEvercore ISIOutperform$20 → $19
Mar-26-26ReiteratedDeutsche BankSell$12 → $14
Mar-26-26ReiteratedWedbushOutperform$29 → $35
Mar-03-26ReiteratedLoop Capital Markets$25
Mar-03-26ReiteratedJefferiesBuy$30
Jan-27-26ReiteratedRobert W. Baird$15 → $22
Dec-09-25InitiatedWedbushOutperform$32
Latest News
Jul-29-26
Jul-29-2605:00PM
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
11:02AM
Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Declinezacks.com
Jul-27-26
Jul-27-2609:19AM
Sarepta names former Abbvie president as CEO as Ingram retiresreuters.com
08:37AM
Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug IngramBenzinga
08:30AM
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officerbusinesswire.com
Jul-22-26
Jul-22-2601:28PM
Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth PotentialSeekingAlpha
10:26AM
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?zacks.com
08:30AM
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Resultsbusinesswire.com
Jul-13-26
Jul-13-2609:46AM
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)globenewswire.com
Jul-11-26
Jul-11-2604:30PM
2 Beaten-Down Stocks That Still Aren't Worth Buyingfool.com
Jul-10-26
Jul-10-2612:04PM
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout247wallst.com
Jul-09-26
Jul-09-2611:36AM
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20Benzinga
Jun-30-26
Jun-30-2604:25PM
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
12:44PM
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy DrugsBenzinga
09:00AM
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®gurufocus.com
Company

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,1842,1981,9021,243933702540381301
Cost of Goods Sold Incl. D&A82288231915014097635734
Gross Profit1,3631,3171,5831,093793605477324267
Selling, General and Administrative Excl. Other467479558482451283318285208
Research and Development9021,522805877877771722561402
Other Operating Expense35-262211111840
Operating Income-41-658218-268-536-460-564-706-344
Interest Expense431018225364603134
Unusual Expense
—————————
Non-Operating Income (Expense)107-3561-230-101104712215
Net Income Before Taxes25-702261-520-690-419-553-714-363
Income Taxes-4011261614011-1
Consolidated Net Income65-713235-536-703-419-554-715-362
Net Income From Continuing Operations65-713235-536-703-419-554-715-362
Net Income65-713235-536-703-419-554-715-362
EPS (Recurring)0.62-7.132.47-5.80-8.03-5.15-7.11-9.71-5.46
EPS (Basic, Before Extraordinaries)0.62-7.132.47-5.80-8.03-5.15-7.11-9.71-5.46
EPS (Diluted)-0.96-7.132.34-5.80-8.03-5.15-7.11-9.71-5.46
EBITDA125-648317-454-595-317-453-659-317
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——51.96——————
Price To Sales Ratio0.791.036.077.1412.2210.3924.6325.0623.93
Gross Margin62.4159.9283.2387.9384.9986.1888.3385.0488.70
Operating Margin-1.88-29.9411.46-21.56-57.45-65.53-104.44-185.30-114.29
Net Margin2.98-32.4412.36-43.12-75.35-59.69-102.59-187.66-120.27
Shares Outstanding10510595928881787466
Market Capitalization1,7212,26011,5518,87211,4037,29413,2989,5497,203
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$47.67$37.57$27.47$17.37$7.27● Close Price0.00K73.55K147.10K220.65K294.20KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mayo StephenDirectorMar 12 '26Sale17.027,239123,2081,765Mar 13
Rodino-Klapac LouisePresident, R&D and Tech OpsMar 01 '26Option Exercise0.008,1250232,155Mar 03
Estepan Ian MichaelChief Operating OfficerMar 01 '26Option Exercise0.008,1250208,875Mar 03
Estepan Ian MichaelChief Operating OfficerFeb 26 '26Option Exercise13.717,450102,140200,750Mar 02
Nicaise ClaudeDirectorJan 29 '26Option Exercise13.7110,500143,95538,312Jan 29
BEHRENS M KATHLEENDirectorJan 27 '26Option Exercise13.7121,000287,910203,976Jan 29
Estepan Ian MichaelChief Operating OfficerDec 16 '25Sale22.3113,187294,202193,300Dec 18
Barry RichardDirectorMay 16 '25Option Exercise32.6312,350402,9812,966,667May 19
Barry RichardDirectorMay 13 '25Option Exercise19.2320,246389,3592,954,317May 15
Nicaise ClaudeDirectorMar 12 '25Option Exercise25.189,746245,40430,303Mar 13
Nicaise ClaudeDirectorMar 12 '25Sale99.642,491248,20327,812Mar 13
Rodino-Klapac LouiseHead of R&D, CSOMar 07 '25Option Exercise0.005,500079,818Mar 11
Murray DallanChief Customer OfficerMar 07 '25Option Exercise0.005,500033,659Mar 11
Estepan Ian MichaelChief Financial OfficerMar 07 '25Option Exercise0.005,500058,277Mar 11
Rodino-Klapac LouiseHead of R&D, CSOMar 06 '25Option Exercise0.0017,500082,822Mar 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.